CWM
ZNTL icon

Cornerstone Wealth Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Cornerstone Wealth Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.8K Buy
+10,186
New +$26.3K ﹤0.01% 710
2022
Q2 		– Sell
-6,607
Closed -$305K – 491
2022
Q1 		$305K Hold
6,607
– – 0.03% 360
2021
Q4 		$555K Sell
6,607
-2,000
-23% -$155K 0.05% 267
2021
Q3 		$574K Sell
8,607
-7,000
-45% -$404K 0.06% 246
2021
Q2 		$830K Hold
15,607
– – 0.09% 207
2021
Q1 		$677K Hold
15,607
– – 0.08% 225
2020
Q4 		$811K Buy
+15,607
New +$704K 0.1% 180

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Cornerstone Wealth Management's ZNTL Position: Q1 2026 in Review

Cornerstone Wealth Management opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 10,186 shares worth $23.8K. The stake represents ﹤0.01% of the portfolio and ranks #710 among its holdings. This is a return to the name: Cornerstone Wealth Management previously reported a position in ZNTL as recently as Q1 2022.

Cornerstone Wealth Management first reported a position in ZNTL in Q4 2020 and has held it in 7 quarters since. The position peaked at $830K in Q2 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Cornerstone Wealth Management held 10,186 shares of Zentalis Pharmaceuticals worth $23.8K as of Q1 2026.
  • Zentalis Pharmaceuticals was a new Cornerstone Wealth Management position in Q1 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Cornerstone Wealth Management's portfolio in Q1 2026, its #710 holding.
  • Cornerstone Wealth Management first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 7 quarters since.
  • Cornerstone Wealth Management's Zentalis Pharmaceuticals position peaked at $830K in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Cornerstone Wealth Management's 13F filing for Q1 2026, filed 24 Apr 2026.